1 / 43

Haematological Malignancy leukaemia and lymphoma,myeloma Concepts and principles Medical Students

Haematological Malignancy leukaemia and lymphoma,myeloma Concepts and principles Medical Students. 2010. Haematological Malignancies concern blood and lymphoid tissue. Myelodysplasia (pre malignant) Acute leukaemia Chronic leukaemias Lymphoma Myeloma. Different growth patterns.

ivana
Télécharger la présentation

Haematological Malignancy leukaemia and lymphoma,myeloma Concepts and principles Medical Students

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Haematological Malignancyleukaemia and lymphoma,myelomaConcepts and principlesMedical Students 2010

  2. Haematological Malignancies concern blood and lymphoid tissue • Myelodysplasia (pre malignant) • Acute leukaemia • Chronic leukaemias • Lymphoma • Myeloma

  3. Different growth patterns Cancer cells Normal cells

  4. Acquired Capabilities, Molecular Pathways, and the Transformation of Human Cells: Emerging Rules That Govern Cancer Formation Hahn, W. C. et al. N Engl J Med 2002;347:1593-1603

  5. A Possible Mechanism of Leukemic Transformation Naparstek, E. N Engl J Med 1995;333:516-518

  6. apotosis • Cells cycle and turn over • Malignant cells • Normal cells

  7. Autophagy • An concept of cell death avoidance

  8. What are the hallmarks of malignancy?

  9. Chronic leukaemia • Chronic myeloid leukaemia • Chronic lymphatic leukaemia

  10. Chronic Lymphatic Leukaemia (CLL) • May present with mild lymphocytosis • May have lymphadenopathy • Hb 13.5g.dl, WCC 15x109/l, platelets normal. Neutrophils 4x109/l, lymphocytosis of 10x109/l • Immunophenotyping on peripheral blood is diagnostic • Uniquely –biopsy not required

  11. Mature B lymphocytes

  12. Therapy for CLL • No therapy • Chemotherapy • Steroids • Immunotherapy: • Rituximab is a monoclonal antibody to CD20 which is expressed on all CLL cells. It is less toxic than chemotherapy and is effective in combination with chemotherapy drugs • Ofatumumab

  13. What are the hallmarks of malignancy?

  14. Chronic Myeloid leukaemia • Typical count • Hb 14.0g/dl • WCC 120x109/l • Platelets 560x109/l • Neutrophils 114x109/l

  15. In CML raised WBC with some immature forms in the blood and often increased eosinophils and basophils . The predominant cell is the neutrophil.

  16. Neutrophil Alkaline Phosphatase (NAP) low or absent

  17. Marrow hypercellular with gross myeloid hyperplasia. Why is there so much growth? What’s driving it?

  18. Translocation of long arm of 22 to long arm of 9.

  19. This results in activation of a hybrid bcr-abl proto-oncogene which can be detected by reverse transcriptase PCR • This oncogene is critically dependant on thyrosine kinase to transmit its intracellular message

  20. Imatinib (Gleevec )….Time May 2001 Staying on Gleevec for life could cost a patient as much as $30,000 per year, though the mag predicts insurance companies will probably pick up the tab now that Gleevec's off the experimental list.

  21. Imatinib Desatinib Nilotinib All licenced in Ireland ThyrosineKinase inhibitors

  22. What are the hallmarks of malignancy? • Is malignancy “easy” to diagnose

  23. What are the hallmarks of malignancy? • Is malignancy “easy” to diagnose • Can malignancy be confused with other diagnoses?

  24. Kikuchi’s disease • Angio immunblastic lymphadenopathy (AILD) • Castlemann’s disease

  25. Lymphoma • Non Hodgkin’s Lymphoma • Hodgkin’s Disease

  26. NHL • T cell • B cell • Histology/biopsy of node • Radiology for staging • Bone marrow for staging

  27. NHL • WHO and other classifications • Aggressive –often curable • Low grade-incurable but reasonable prognosis…

  28. Treatment of Lymphomas • Chemotherapy • Steroids • Immunotherapy: • Rituximab is a monoclonal antibody to CD20 which is expressed on all CLL cells. It is less toxic than chemotherapy and is effective in combination with chemotherapy drugs • Radiotherapy • Radio-immunotherapy (Yttrium-90) • Novel agents, lenalidomide,bortazemib

  29. Also ofatumumab – a fully humanised anti- CD20 in trials in CUH and elsewhere

  30. Myeloma • The malignant cell is the plasma cell • Plasma cells secrete….. • The malignant cell is clonal… • Therefore the paraprotein is clonal… • A monoclonal gammopathy

  31. Plasma cells in myeloma

  32. Therapy of myeloma • Chemotherapy • Prednisolone and other steroids • Thalidomide (angiogenesis inhibitors) • Proteosome inhibitors Bortazemib • Lenalidomide • Experimental agents – include monoclonal antibodies

  33. Myeloproliferative disorders • Chronic myeloid leukaemia (CML) • Polycythaemia rubra vera (PRV) • Essential thrombocytosis (ET) Janus Activated Kinase JAK 2 • Myelofibrosis (MF)

  34. Further targeted therapy • JAK 2 inhibitor therapy • NEJM 2010

  35. MYELOFIBROSIS

  36. What are the hallmarks of malignancy? • Is malignancy “easy” to diagnose • Can malignancy be confused with other diagnoses?

  37. Myelodysplasia (MDS)

More Related